Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;98(2):317-328.
doi: 10.1002/ana.27270. Epub 2025 Jun 6.

New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond

Joseph J Sabatino Jr  1 , Bruce A C Cree  1 , Stephen L Hauser  1
Affiliations
Review

New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond

Joseph J Sabatino Jr et al. Ann Neurol. 2025 Aug.

Abstract

The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, guided by gains in understanding the fundamental immunology, neurobiology, genetics, and triggers of this disease, have broadened the traditional focus on treatment, adding realistic possibilities for prevention and repair. Here, we summarize recent advances that have together transformed the disease from the most common crippler of young adults in the western world to its place today as a condition in which most newly diagnosed patients can anticipate lives free from disability. ANN NEUROL 2025;98:317-328.

PubMed Disclaimer

Conflict of interest statement

J.J.S. has received research support from Novartis AG and Genentech and has received consulting fees from IgM Biosciences and TG Therapeutics. B.A.C. has received research support from Genentech and Kyverna and has received consulting fees from Alexion, Atara, Autobahn, Avotres, Biogen, Boston Pharma, EMD Serono, Hexal/Sandoz, Horizon, Kyverna, Neuron23, Novartis, Sanofi, Siemens and TG Therapeutics. S.L.H. has received consulting fees from BD, Gilead, Moderna, NGM Bio, Nurix Therapeutics, and Pheno Therapeutics, has received travel support from F. Hoffmann‐La Roche and Novartis AG, and has participated on advisory boards for Accure, Alector, Annexon, Hinge Bio, and Neurona.

References

    1. Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease‐modifying therapy in patients with multiple sclerosis. JAMA Neurol 2019;76:536–541. - PMC - PubMed
    1. Brown JWL, Coles A, Horakova D, et al. Association of Initial Disease‐Modifying Therapy with Later Conversion to secondary progressive multiple sclerosis. JAMA 2019;321:175–187. - PMC - PubMed
    1. He A, Merkel B, Brown JWL, et al. Timing of high‐efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 2020;19:307–316. - PubMed
    1. Buron MD, Chalmer TA, Sellebjerg F, et al. Initial high‐efficacy disease‐modifying therapy in multiple sclerosis. Neurology 2020;95:e1041–e1051. - PubMed
    1. Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing–remitting multiple sclerosis: data from 2 different National Strategies. JAMA Neurol 2021;78:1197–1204. - PMC - PubMed

MeSH terms